Apo2L/TRAIL (tumor necrosis factor-related apoptosis inducing ligand (TRAIL), also known as Apo2L) is a potentially important anticancer agent awaiting clinical trials. Unfortunately, however, some cancer cells exhibit resistance to Apo2L/TRAIL, which could limit the use of this potentially promising anticancer agent. Although the molecular basis of the inherent or acquired resistance to Apo2L/TRAIL remains unclear, previous studies indicate that Bax deficiency can confer resistance to Apo2L/ TRAIL. Proteasome inhibition is also emerging as a promising therapeutic strategy to manage human malignancies. Here, we report that proteasome inhibitor MG132 upregulates Apo2L/TRAIL death receptor 5 expression in both Bax-proficient and -deficient HCT116 cells. MG132 effectively cooperated with Apo2L/TRAIL to induce apoptosis in both Bax-proficient and -deficient cells that was coupled with caspases-8 and -3 activation and Bid cleavage. Although both agents in combination also induced cytochrome c and Smac release from mitochondria into cytosol and activated caspase-9 in Bax-proficient cells, their effects on these events were significantly diminished in Bax-deficient cells. These results suggest that Bax is not absolutely required for death receptor 5-dependent apoptotic signals and MG132 by upregulating DR5 effectively cooperates with Apo2L/ TRAIL to overcome Bax deficiency-induced resistance to Apo2L/TRAIL. Our results have important clinical implications in that the use of Apo2L/TRAIL and proteasome inhibitors in combination could prove to be a novel therapeutic strategy to manage the Apo2L/TRAILresistant tumors.
Oncogene ( Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), also known as Apo2L (hereafter referred to as Apo2L/TRAIL), is a novel cytokine that belongs to TNF family of ligands. It is expressed as a type 2 membrane protein and due to proteolytic cleavage of the extracellular domain also exists in soluble form (LeBlanc and Ashkenazi, 2003) . Apo2L/TRAIL mediates its apoptotic effects by binding to its membrane death receptors including death receptor 4 (DR4) and DR5 (also known as TRAIL-R1 and TRAIL-R2, respectively) (Schulze-Osthoff et al., 1998; Singh et al., 1998; Ashkenazi and Dixit, 1999a; LeBlanc and Ashkenazi 2003) . Apo2L/TRAIL also binds to two other receptors named TRAIL-R3 (Degli-Esposti et al., 1997b; Pan et al., 1997; Sheridan et al., 1997) and TRAIL-R4 (Degli-Esposti et al., 1997a; Marsters et al., 1997; Pan et al., 1998) . These receptor are dubbed antiapoptotic decoy receptors since TRAIL-R3 is a GPI-linked molecule lacking the death domain, whereas TRAIL-R4 carries a deleted version of the death domain and accordingly, both cannot transduce apoptotic signals (Degli-Esposti et al., 1997a, b; Marsters et al., 1997; Pan et al., 1997; Sheridan et al., 1997; Pan et al., 1998) . Osteoprotegerin (OPG) is another decoy molecule that interacts with Apo2L/TRAIL and exists in soluble form (Simonet et al., 1997) . TRAIL-R3, TRAIL-R4 and OPG are believed to blunt the apoptotic effects of Apo2L/TRAIL by competing with DR4 and DR5 for Apo2L/TRAIL binding (LeBlanc and Ashkenazi, 2003) .
Aop2L/TRAIL has garnered considerable attention as a novel anticancer agent since it appears to selectively induce apoptosis in cancer cells, but not in normal cells representing various tissue types (LeBlanc and Ashkenazi, 2003) . Exogenously administered Apo2L/ TRAIL has also shown considerable promise as an anticancer agent in vivo in that it inhibits the growth of implanted tumors without much systemic toxicity to animals (Ashkenazi et al., 1999b; Walczak et al., 1999) . Clearly, Apo2L/TRAIL is a promising novel anticancer agent that is expected to enter clinical trials. Unfortunately, however, Apo2L/TRAIL is not effective in all types of malignant cells and some tumor types exhibit resistance to Apo2L/TRAIL (Nesterov et al., 2001) . The molecular basis of Apo2L/TRAIL resistance noted in some tumors is not clear. There is a lack of correlation between Apo2L/TRAIL resistance and the levels of its decoy receptors in certain Apo2L/TRAIL-resistant cells, which suggests a mechanism of resistance other than the decoy receptor expression (Griffith and Lynch, 1998) . A better understanding of the regulation of Apo2L/ TRAIL receptors and that of the signaling events originating from them is expected to improve the therapeutic value of this potentially important anticancer agent. Such information may also help in elucidating the molecular basis of differential sensitivity of transformed and normal cells to Apo2L/TRAIL.
Several lines of recent evidence indicate that p53 and many clinically relevant anticancer agents induce Apo2L/TRAIL death receptor DR5 expression (Wu et al., 1997; Sheikh et al., 1998; Nimmanapalli et al., 2001; He et al., 2002b) . Accordingly, Apo2L/TRAIL has been shown to augment the effects of other agents that upregulate DR5 (Nagane et al., 2000; Nimmanapalli et al., 2001; He et al., 2002a He et al., , b, 2003 LeBlanc et al., 2002) . Thus, the utility of Apo2L/TRAIL in combination with other anticancer agents that upregulate DR5 expression is believed to prove superior approach than Apo2L/TRAIL alone, particularly for tumors that exhibit resistance to Apo2L/TRAIL. In our preliminary studies, we had found that the proteasome inhibitor MG132 upregulates DR5 expression. The proteasome inhibitors have also generated significant interest as potential cancer therapeutic agents (Adams and Elliott, 2000; Adams, 2003; Richardson et al., 2003) . For example, the proteasome inhibitor bortezomib (also known as PS-341 or Velcade) has recently been approved by the FDA for the treatment of multiple myeloma (Richardson et al., 2003) . Clinical trials are currently underway to also test its utility for other types of malignancies (Lenz, 2003) . In view of the significance of Apo2L/TRAIL and the proteasome inhibitors as potentially important cancer therapeutics, we sought to investigate whether the proteasome inhibitor MG132 by upregulating DR5 would cooperate with Apo2L/ TRAIL to induce apoptosis in general, and Apo2L/ TRAIL-resistant cancer cells in particular.
Others and we have recently reported that Bax deficiency in HCT116 human colon cancer cells makes them resistant to Apo2L/TRAIL El-Deiry, 2001, Deng et al., 2002; He et al., 2002b He et al., , 2003 LeBlanc et al., 2002) . We used Bax-proficient and -deficient HCT116 cells to investigate MG132 regulation of DR5. As shown in Figure 1a , MG132, in a concentrationdependent manner, upregulates DR5 mRNA levels in both Bax-deficient and -proficient cells although its effect is more pronounced in Bax-deficient cells. To test whether MG132 upregulation of DR5 mRNA levels was coupled with increases at the DR5 protein levels, we performed Western blot analysis on MG132-treated and untreated Bax-proficient and -deficient cells. Figure 1b shows that MG132 also upregulates the DR5 protein levels. Next, we investigated the MG132 and Apo2L/ TRAIL interactions on cell viability and apoptosis in these cells. As shown in Figure 2a and b, Bax-proficient cells are sensitive to Apo2L/TRAIL, whereas Baxdeficient cells are resistant, which is consistent with our previous results (He et al., 2002b (He et al., , 2003 . Baxproficient cells are also somewhat sensitive to MG132 but the Bax-deficient cells are not, and the combination of MG132 and Apo2L/TRAIL promotes apoptosis and significantly reduces cell viability in both Bax-deficient and -proficient cells (Figure 2a and b) . These results indicate that MG132 cooperates with Apo2L/TRAIL to overcome Apo2L/TRAIL resistance caused by Bax deficiency.
To explore the molecular basis of the interactions between Apo2L/TRAIL and MG132 in Bax-proficient and -deficient HCT116 cells, we investigated their effect on the intracellular apoptotic molecules that are engaged by the extrinsic and intrinsic pathways. Figure 3 shows that MG132 (0.5 mM) or Apo2L/TRAIL (10 ng/ml) in combination induce activation of caspases-8 and -3 in both Bax-proficient and -deficient cells. The combination of both agents also efficiently induces -4) for approximately 24 h. Cells were harvested and total RNA was subjected to Northern analysis as we have previously described (Huang et al., 2001) . A cDNA fragment corresponding to human DR5 was used as a probe; ethidium bromide staining of the gel is shown to indicate RNA integrity. (Figure 3 ). Since the combination of both also effectively induces apoptosis in Bax-proficient and Bax-deficient cells (Figure 2) , these results would suggest that although Bax is appeared to be needed for caspase-9 activation, active caspase-9 may not be absolutely required during the apoptotic interactions between these two agents.
Cytochrome c and Smac are the mitochondrial proteins that are released into cytosol upon activation of the intrinsic pathway of apoptosis (Wang, 2001; Shi, 2002; Verhagen and Vaux, 2002) . Next, we investigated whether the combination of MG132 and Apo2L/ TRAIL would affect the release of these molecules from mitochondria into cytosol. To this end, we analysed the cytosolic fractions from untreated and Apo2L/TRAIL and/or MG132-treated cells. The results presented in Figure 4 indicate that MG132 and Apo2L/TRAIL in combination strongly induce the release of cytochrome c and Smac into cytosol in Bax-proficient cells, but their effect was clearly diminished in Bax-deficient cells. These results thus suggest that in Bax-deficient cells, the absence of Apo2L/TRAIL-induced cytochrome c and Smac release into cytosol appear to also affect caspase-9 activation.
From the preceding results it is clear that both agents in combination engage the extrinsic and intrinsic pathways of apoptosis as is evidenced by their ability to activate caspase-8, -9 and -3 and the release of To determine cell viability (a) Bax-proficient (Bax þ /À ) or -deficient (Bax À/À ) HCT116 cells were either left untreated or exposed to MG132 (MG, 0.5 mM) and/or Apo2L/TRAIL (TRL, 10 ng/ml) for approximately 8 h and then processed for MTT assay. MTT assay was performed as described by Mosmann (1983) with modification. To determine apoptosis (b), floating and adherent cells were counted using a phase contrast microscope as reported previously (He et al., 2002b (He et al., , 2003 . The values represent mean 7s.e.m. of three independent experiments Figure 3 Representative Western blots showing MG132 and/or Apo2L/TRAIL effect various intracellular apoptotic molecules in Bax-proficient and Bax-deficient cells. Bax-proficient (Bax þ /À ) or -deficient (Bax À/À ) cells were either not treated or treated with MG132 (MG, 0.5 mM), Apo2L/TRAIL (TRL, 10 ng/ml) or the combination of both for approximately 8 h. Cells were harvested and subjected to Western blot analysis; same blot was sequentially probed with anti-caspases-8, -9 and -3 antibodies (PharMingen). The same blot was also probed with anti-b-actin antibody to determine comparable loading in each lane Figure 4 Effect of Apo2L/TRAIL (TRL) and MG132 (MG) on cytochrome c and Smac release from mitochondria into cytosol. Bax-proficient (Bax þ /À ) or Bax-deficient (Bax À/À ) cells were either not treated or treated with MG132 (MG, 0.5 mM), Apo2L/TRAIL (TRL, 10 ng/ml) or the combination of both for approximately 8 h. Cytosolic fractions were prepared as we have previously described (He et al., 2002b (He et al., , 2003 and Western blot analysis was performed by standard procedures. To detect cytochrome c a monoclonal anti-cytochrome c antibody (PharMingen) was used, whereas a monoclonal anti-Smac antibody (Upstate Cell Signaling Solutions, Lake Placid, NY, USA) was used to detect Smac. The same blot was also probed with anti-b-actin antibody to determine comparable loading in each lane Cooperation between Apo2L/TRAIL and proteasome inhibitor Q He et al mitochondrial proteins in Bax-proficient cells. Both also activate caspase-8 in Bax-deficient cells but the intrinsic pathway is not fully activated. These results would suggest that there appears to be a defect in the potential crosstalk between the extrinsic and intrinsic pathways due to Bax deficiency. Bid is a Bcl-2 family protein that is known to bridge a crosstalk between extrinsic and intrinsic pathways of apoptosis (Scorrano and Korsmeyer, 2003) . For example, caspase-8 is an apical caspase in the extrinsic pathway that upon activation cleaves Bid, truncated Bid (tBid) translocate to mitochondria and interacts with Bax and Bak to engage the intrinsic pathway (Korsmeyer et al., 1999; Scorrano and Korsmeyer, 2003; Wei et al., 2001) . Next, we sought to explore whether Bid cleavage is altered due to Bax deficiency, and as shown in Figure 5 , the level of fulllength Bid is decreased in both Bax-proficient and -deficient cells treated with the combination of MG132 and Apo2L/TRAIL. The anti-Bid antibody does not detect the cleaved fragment of Bid but a decrease in the full-length Bid levels is reflective of its cleavage and activation (He et al., 2002a (He et al., , b, 2003 . These results thus suggest that Bax deficiency does not significantly affect Bid cleavage in these cells. These results would also suggest that the defect in the activation of intrinsic pathway in Bax-deficient cells appears to lie downstream of Bid cleavage in these cells.
In this study, we have investigated whether the proteasome inhibitor MG132 by upregulating the Apo2L/TRAIL death receptor DR5 would cooperate with Apo2L/TRAIL to induce apoptosis in general and in Apo2L/TRAIL-resistant human cancer cells in particular. Bax-deficient cells have been found to be resistant to Apo2L/TRAIL (Burns and El-Deiry, 2001; Deng et al., 2002; He et al., 2002b He et al., , 2003 LeBlanc et al., 2002) . We therefore, utilized Bax-proficient and Baxdeficient HCT116 human colon cancer cells and found that MG132 upregulates the DR5 expression in both Bax-proficient and -deficient cells. These results indicate that Bax deficiency does not affect the MG132 regulation of DR5 expression. Our results also indicate that Apo2L/TRAIL and MG132 in combination were more effective in mediating apoptosis in both Bax-proficient and -deficient cells. The combination of MG132 and Apo2L/TRAIL induced the activation of caspases-8 and -3, and that of the intrinsic pathway (including cytochrome c and Smac release and caspase-9 activation) in Bax-proficient cells. The combination of both agents also promoted caspases-8 and 3 activation in Bax-deficient cells, although the cytochrome c and Smac release into cytosol and caspase-9 activation were affected. We and others have previously shown that the same Bax-deficient cells do not exhibit caspase-9 activation in response to other types of apoptotic stimuli (He et al., 2002b (He et al., , 2003 Yamaguchi et al., 2003) . Our results, therefore, suggest that the combination of MG132 and Apo2L/TRAIL by engaging DR5, that is the extrinsic pathway, appears to overcome the Bax deficiency-induced defects in the intrinsic pathway.
Recent explosion of information on apoptosis suggests that deregulation of apoptosis appears to also play a role in malignant transformation and progression (Nicholson, 2000; Reed, 2002) . Alterations in apoptotic signaling pathways in tumor cells have also been implicated in promoting anticancer drug resistance (Nicholson, 2000; Reed, 2002) . Thus, a better understanding of the molecular mechanisms that control apoptosis in both normal and tumor cells is likely to help develop novel and more efficacious anticancer therapies. Consistent with this notion, the discovery and utility of anticancer agents to target apoptotic machinery are intensely pursued (Nicholson, 2000; Reed, 2002) . Others and we have previously reported that Bax-deficient cells are relatively more resistant to the apoptotic effects of Apo2L/TRAIL than the Bax-proficient cells (Burns and El-Deiry, 2001; Deng et al., 2002; He et al., 2002b He et al., , 2003 LeBlanc et al., 2002) . Mutational inactivation of Bax has been reported to occur in various human malignancies including colon cancer (Zhang et al., 2000 and references therein) . Primary tumors harboring inactive Bax are predicted to also exhibit Apo2L/ TRAIL resistance. It is therefore possible that the therapeutic promise of Apo2L/TRAIL in Bax-deficient tumors could be improved by combining this novel ligand with other agents that upregulate its death receptor(s). In this regard, our present results demonstrate that the proteasome inhibitor MG132 by upregulating DR5 cooperates with Apo2L/TRAIL to induce apoptosis in both Bax-proficient and -deficient cells. Thus, MG132 interacts with Apo2L/TRAIL to overcome Apo2L/TRAIL resistance conferred due to Bax deficiency. These results are likely to have important clinical implications in that the proteasome inhibitors are being developed as novel anticancer therapeutics; Aop2L/TRAIL, owing to its differential apoptotic effect on normal versus cancer cells, is expected to enter clinical trials (Ashkenazi et al., 1999b; Walczak et al., 1999) . Thus, the utility of Apo2L/TRAIL in combination with proteasome inhibitors could prove to be a novel cancer therapeutic strategy particularly to manage the Apo2L/TRAILresistant tumors. Figure 5 Effect of Apo2L/TRAIL (TRL) and MG132 (MG) on Bid cleavage in Bax-proficient (Bax þ /À ) and Bax-deficient (Bax À/À ) cells. Cells were either not treated or treated with MG132 (MG, 0.5 mM), Apo2L/TRAIL (TRL, 10 ng/ml) or the combination of both for approximately 8 h and the cytosolic fractions were subjected to Western blot analysis using a polyclonal anti-Bid antibody (R&D Systems, Minneapolis, MN, USA). The same blot was also probed with anti-b-actin antibody to determine comparable loading in each lane Cooperation between Apo2L/TRAIL and proteasome inhibitor Q He et al
